ResMed – Quality Trade

Stock Takes

We have caught the knife buying RMD for a trade after a 25% collapse in the share price, which, as you can see below, has broken a long-term uptrend. That sell-off came after recent results (August7 2023) which missed sales forecast by 2% and saw margins down 2.1% to 55.8%. Margins were the issue, although they were only 0.3% below expectations. Brokers adjusted numbers downwards after the results to account for narrower margins and higher costs (inflation). Risks include Philips getting back into the market and suggestions that weight loss drugs could take off which would reduce the need for OSA devices.

Marcus Take Thursday

Box 1

MARCUS TAKE SUMMARY Regrets, I’ve had a few. See today’s article on the millions I have missed. Thanks for your feedback on the members podcast. I read them all! Bit of a change to the technical section. Now included in my section. Stock Take on CSL – Trading buy. And a long term buy. I…

Henry’s Take – You Cannot be Serious!

Box 2

SMALL CAP PORTFOLIO 2.45pm Update The market all hot and bothered again. Big Trouble in Little China. But the jobs numbers at 3.7% show that the medicine that Dr Phil has prescribed is working and we may not need another dose. That is a good thing. I bought some more LTR. Could not help myself.…

Midday Report Thursday

Reports Section

MARKET AT MIDDAY The ASX 200 is down 59 points to 7136 (-0.8%), sliding to a 5-week low as earnings reports and the release of July jobs data push the market lower. Telstra (TLS) led the communications sector down, dropping 2.6% as Instructure sale called off. Lithium stocks, healthcare, and technology sectors all declining, with Pilbara Minerals (PLS) -3.1%, Core Lithium (CXO) -22%, Resmed (RMD) -4.1%, Sonic Healthcare (SHL) -5.1%, Xero (XRO) -1.9%,…